Skip to main content

Table 1 Antiretroviral therapy and drug resistance mutation over time in study subjects

From: Transmission of Human Immunodeficiency Virus I Drug Resistance - a Case Report. What are the Clinical Implications?

Patient Year Antiretroviral therapy   mutations associated with resistance Virus load
Copies/ml
M 1993 AZT    n.d.
  1995 AZT, 3TC    
  12/1997 d4T, 3TC    
  1999     4700
  07/2004    RT: M41L, M184V, T215Y, (T39A, V60I, D121Y, I135T, I142V1, D177G, V179I, T200A, Q207E, L214f, L228H, Q334H) 26929
     PR: L63P, I13V, (V3I, K14R, S37N)  
    CS p1/p6-gag: L449V, S451N  
  08/2004 ATV/r, EFV    
  01/2005     < 50
  04/2005 ATV/r, EFV, 3TC    < 50
W 08/2006    RT: M41L, T215D, (T39A, V60I, D121Y,135T,N137S,I142V, S162C, I202I/V, Q207E/K, l214F, l228H) > 500.000
     PR: L63P, I13V, (E35D, S37N/S, S37N, V3I)  
    CS p1/p6-gag: L449V, S451N  
  09/2006 TVd, INV/r    
  10/2008 TVd, ATV/r    < 40
  11/2008     1381
  12/2008     132
  02/2008     8515
  03/2009    RT: M41L, T215D, (T39A,V601I D121Y, K122E,135T,N137S,I142V S162C, I202IV, Q207E/K, L214F, L228H, V245M, A272P, T286A, E297K)  
     PR: L63P, I13V, E35D  
    CS p1/p6-gag: l449V, S451N  
  04/2009 NVP, DRV/r    
  06/2009     < 40
  11/2009     < 40
  1. M = husband/suspected source of infection, W = case-patient